TRex Bio (NASDAQ:TRXB) Coverage Initiated by Analysts at Wedbush

Equities research analysts at Wedbush assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a report released on Monday, Briefing.com reports. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Wedbush‘s price target would suggest a potential upside of 118.34% from the company’s previous close.

TRex Bio Stock Performance

Shares of NASDAQ:TRXB opened at $13.74 on Monday. TRex Bio has a 12 month low of $13.10 and a 12 month high of $16.56.

Insider Buying and Selling

In other TRex Bio news, major shareholder Alexandria Venture Investments acquired 178,571 shares of the company’s stock in a transaction on Tuesday, October 13th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the acquisition, the insider owned 1,346,501 shares in the company, valued at $18,851,014. This represents a 15.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.